ORPHAZYME A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,090 DKK | -0.91% |
|
+4.11% | -18.05% |
| Mar. 27 | Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 04 | FDA Extends Review of Zevra's Arimoclomol by Three Months | DJ |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 864.4 | 1,447 | 2,328 | 599.8 | 31.07 | 46.96 |
| Enterprise Value (EV) 1 | 469.6 | 1,400 | 1,672 | 537.5 | -11.39 | 28.75 |
| P/E ratio | -3.77 x | -4.29 x | -3.01 x | -0.96 x | 1.19 x | -1.8 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | 16,571,611 x | - | - |
| EV / Revenue | - | - | - | 14,850,643 x | - | - |
| EV / EBITDA | -2.04 x | -4.19 x | -2.76 x | -0.94 x | 0.41 x | -2.38 x |
| EV / FCF | -3.08 x | -6.68 x | -5.33 x | -1.44 x | 0.18 x | -16 x |
| FCF Yield | -32.4% | -15% | -18.8% | -69.5% | 563% | -6.26% |
| Price to Book | 2.23 x | 27.3 x | 3.75 x | 64.2 x | 0.75 x | 3.3 x |
| Nbr of stocks (in thousands) | 19.9 | 20 | 34.7 | 35 | 35.3 | 35.3 |
| Reference price 2 | 43,350 | 72,400 | 67,100 | 17,160 | 880.0 | 1,330 |
| Announcement Date | 3/1/19 | 2/28/20 | 3/2/21 | 6/7/22 | 4/25/23 | 3/27/24 |
1DKK in Million2DKK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | 36.19 | - | - |
| EBITDA 1 | -230.3 | -334.2 | -606.4 | -571.9 | -28.03 | -12.1 |
| EBIT 1 | -231.7 | -336 | -608.5 | -586.7 | -41.24 | -12.88 |
| Operating Margin | - | - | - | -1,621.04% | - | - |
| Earnings before Tax (EBT) 1 | -235.1 | -343 | -635.2 | -631.5 | -41.05 | -26.05 |
| Net income 1 | -229.6 | -337.5 | -633.2 | -626.5 | 26.07 | -26.05 |
| Net margin | - | - | - | -1,731.11% | - | - |
| EPS 2 | -11,500 | -16,873 | -22,324 | -17,940 | 739.2 | -737.7 |
| Free Cash Flow 1 | -152.4 | -209.6 | -313.7 | -373.4 | -64.09 | -1.8 |
| FCF margin | - | - | - | -1,031.77% | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/1/19 | 2/28/20 | 3/2/21 | 6/7/22 | 4/25/23 | 3/27/24 |
1DKK in Million2DKK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 395 | 46.5 | 656 | 62.3 | 42.5 | 18.2 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -152 | -210 | -314 | -373 | -64.1 | -1.8 |
| ROE (net income / shareholders' equity) | -45.7% | -153% | -188% | -199% | -150% | -94.3% |
| ROA (Net income/ Total Assets) | -26.2% | -67.5% | -75.8% | -73.7% | -22.3% | -21.2% |
| Assets 1 | 875.5 | 500 | 835.2 | 850.7 | -117 | 123.1 |
| Book Value Per Share 2 | 19,471 | 2,650 | 17,884 | 267.0 | 1,180 | 403.0 |
| Cash Flow per Share 2 | 19,795 | 6,184 | 20,950 | 2,926 | 1,203 | 319.0 |
| Capex 1 | 0.74 | 2.78 | 2.37 | 0.09 | - | - |
| Capex / Sales | - | - | - | 0.25% | - | - |
| Announcement Date | 3/1/19 | 2/28/20 | 3/2/21 | 6/7/22 | 4/25/23 | 3/27/24 |
1DKK in Million2DKK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -18.05% | 5.51M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ORPHA Stock
- Financials Orphazyme A/S
